US healthcare stocks struggle in 2025 due to government policies, sparking interest from bargain hunters as valuations reach ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech TÜBINGEN, Germany / BOSTON, USA – August 7/8, 2025 ...

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Europe's pharmaceutical companies are bracing for United States President Donald Trump's plan to slap tariffs of up to 250 ...

The government is in talks with pharmaceutical companies to raise the prices of certain medications outside the U.S.

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GSK's GSK -1.53% Get Free Report short percent of float has fallen 27.17% since its last report. The company recently reported that it has 13.51 million shares sold short, which is 0.67% of all ...

Pfizer is the closest company to producing a Lyme disease vaccine. Experts are concerned that vaccine skepticism could stand in its way.